Scotiabank analyst Greg Harrison maintained his Outperform rating on Vera Therapeutics, Inc. (NASDAQ:VERA) shares and raised his price objective from $55 to $65 for the company.
A team of scientists in lab coats discussing research near a microscope and petri dishes.
The analyst informs investors that the business recently released positive topline data from the phase 3 ORIGIN study of atacicept, which showed that treatment with atacicept reduced proteinuria by 42% when compared to the placebo.
Despite the competitive environment, the company considers that it is in a good position to take a significant share of the expanding IgAN.
Vera Therapeutics, Inc. is a biotechnology startup in the clinical stage. Its main goal is to create and market revolutionary therapies for people suffering from severe immune disorders.
The company’s product candidate is atacicept, a fusion protein that is self-administered once a week via subcutaneous injection. It inhibits a proliferation-inducing ligand and a B lymphocyte stimulator, which cause B cells and plasma cells to produce autoantibodies that contribute to specific autoimmune diseases.
READ NEXT: 10 High-Growth EV Stocks to Invest In and 13 Best Car Stocks to Buy in 2025.
Disclosure. None.
